How to use Technologies offered

A search for a cancer, preclinical stage, synthetic opportunity would use the selection "Therapeutics, Diagnostics" in 'Sector', 'Cancerous, neoplasmatic' in 'Disease Category', 'Drugs, Small Molecule' in 'Technology' and 'Preclinical' in 'Development Stage'.

Selection of 'Enabling Technology, Platform Technology' in 'Sector' will identify all kinds of research technologies that can be used in more areas of life sciences than pharmaceuticals only.

Each technology profile gives the name of a company or academic institute as source of the offer, and a link allowing to contact the potential licensor. In most cases a profile includes a pdf covering the available non-confidential information as well as detailed contact data.

Registered users can create non-public notifications profiles which will inform them about new 'Technologies Offered' entries fitting their needs as specified. In addition these profiles allow them to filter the available information more comfortably.



Organization name

PROvendis GmbH


Selective Enhancement of Ligands by Exponential Enrichment (SELEX) has proven to be a powerful tool for idenfying functional oligonucleotides which bind to selected targets. Here, in an iterative process, a pool of single stranded oligonucleotides is contacted with a target structure (e.g. a protein), high-affinity oligonucleotides are then isolated, amplified and again put into contact with the target until, eventually, an ideal oligonucleotide has been obtained.

SELEX has opened up new avenues e.g. for generating aptamers as therapeutic compounds - and thereby enlarging the space for novel lead structures. However, the chemical space and thus the number of targetable proteins is still restricted by the limited diversity of nucleic acids. Use of chemically modified nucleic acids can solve this issue, but such nucleotides often lack compatibility with enzymatic steps (e.g. PCR) of the in vitro selection process.

Here, a versatile method (Click-SELEX) has been developed for the modular expansion of the chemical space of nucleic acid libraries, thus enabling the generation of nucleobase-modified aptamers with unprecedented recognition properties. The introduction of additional chemical entities into the DNA is achieved by using a 5’ modified, commercially available nucleoside-triphosphate whereas the modification can be further derivatized with so-called bio-orthogonal chemistry, e.g. click-chemistry.

Advantageously, the modification is only transiently present during the selection cycle. This enable a high degree of compatibility with the enzymatic step of the selection process. This approach further allows introducing larger chemical entities into DNA libraries that cannot be used using current methods.
The click chemistry has a broad acceptance of diverse substrates, which are either commercially available or accessible by chemical synthesis.

Commercial Opportunities

On behalf of University of Bonn, PROvendis offers licenses for commercial use as well a research collaboration with licensing option.

Current Status  

An International and a European patent application are pending:
International Patent Application WO 2015/049359
International Patent Application WO 2016/050850

To view the contact information, attachments and url of this profile you have to login into your account or register a new account: Login Register

Your feedback

Please click here to log in to view the complete profile.


latest entries